Amir Ghasemi Jangjoo, Hosein Ghiasi and Asghar Mesbahi
characterization of the first AMIRS 103Pd brachytherapy source. Appl Radiat Isot 2008;66(12):1856-60.
 Kim YJ, Park JH, Yun IH, Kim YS. A prospective comparison of acute intestinal toxicity following whole pelvic versus small field intensity-modulated radiotherapy for prostatecancer. Onco Targets Ther. 2016;9:1319-25.
 Xie WZ, Friedland WF, Li WB, et al. Simulation on the molecular radiosensitization effect of gold nanoparticles in cells irradiated by x-rays. Phys Med Biol 2015; 21;60(16):6195-212.
 Yang CJ, Chithrani DB. Nuclear Targeting of Gold
Kovacs Zsolt, Tripon Robert, Nemes Nagy Eniko, Balogh Samarghitan Victor, Tilinca Mariana, Martha Orsolya and Fazakas Zita
Arylsulfatase A (ARSA) is a lysosomal enzyme that plays an important role in catalysis of degradation of cerebrosidesulphate. The deficiency of this lysosomal enzyme causes an autosomal recessive disorder, called metachromatic leucodystrophy. However, a low ARSA activity can be observed in clinically healthy people, called ARSA pseudodeficiency. In our study we investigated the possible linkage between ARSA activity and sulfatide deficiency causing characteristic aspects of degenerative diseases, such as end stage kidney disease, type 2 Diabetes mellitus, Parkinson syndrome, prostate cancer and HIV (Human Immunodeficiency Virus) infection. We used a spectrophotometric method to determine the activity of ARSA. This method of enzyme dosage is based on a 4 hour long hydrolysis of the ARSA enzyme on 4-nitrocatechol sulfate (p-NCS) substrate. The unit of this measurement is nmol/ml/4h. Our findings show significant values in type 2 diabetes, Parkinson syndrome and chronic kidney disease. The importance of sulfatide in these diseases is well-known, thus presumably the variation of the ARSA’s activity might play an important role in the pathophysiology of these diseases, involving a vicious cycle between sulfatide degradation andthese diseases.
Sang Won Kang, Jin Beom Chung, Jae Sung Kim, In Ah Kim, Keun Yong Eom, Changhoon Song, Jeong Woo Lee, Jin Young Kim and Tae Suk Suh
Prostatecancer is the most common cancer in men, accounting for over one fifth of male cancer diagnoses, with the number of prostatecancer patients rapidly increasing. Various radiotherapy techniques for treating prostatecancer have been considered effective noninvasive treatment options, especially for elderly patients and those unfit for surgery. 1 - 3
Radiation therapy options for prostatecancer include external beam radiation therapy (EBRT) and brachytherapy. Volumetric modulated arc therapy (VMAT) and intensity-modulated radiation
Ivana Vrhovac Madunić, Josip Madunić, Davorka Breljak, Dean Karaica and Ivan Sabolić
50. Ghezzi C, Wright EM. Regulation of the human Na+- dependent glucose cotransporter hSGLT2. Am J Physiol-Cell Ph 2012;303:C348-54. doi: 10.1152/ajpcell.00115.2012
51. Siegel RL, Miller KD, Jemal A. Cancer Statistics. CA Cancer J Clin 2017;67:7-30. doi: 10.3322/caac.21387
52. Vaz CV, Marques R, Alves MG, Oliveira PF, Cavaco JE, Maia CJ, Socorro S. Androgens enhance the glycolytic metabolism and lactate export in prostatecancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. J Cancer Res Clin Oncol
 Tanaka O, Hayashi S, Matsuo M, et al. Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;66(2):597-602.
 Tanaka O, Hattori M, Hirose S. Comparison of the MRI sequences in ideal fiducial marker-based radiotherapy for prostatecancer. Radiother Oncol. 2016;119(Supplement1):S858-S859.
Anna Kowalik, Weronika Jackowiak, Julian Malicki, Małgorzata Skórska, Marta Adamczyk, Ewelina Konstanty, Tomasz Piotrowski and Kinga Polaczek-Grelik
and neck radiotherapy using IMRT and 3D-CRT. Radiol. Oncol ., 46 (4), 328–336.
10. Van den Heuvel, F., Defraene, G., Crijns, W., & Bogaerts, R. (2012). Out-of-field contributions for IMRT and volumetric modulated arc therapy measured using gafchromic films and compared to calculations using a superposition/convolution based treatment planning system. Radiother. Oncol ., 105 (1), 127–132.
11. Skórska, M., & Piotrowski, T. (2013). Optimization of treatment planning parameters used in tomotherapy for prostatecancer patients. Phys. Med ., 29 (3), 273
Reske SN. Nuclear imaging of prostatecancer: current status. Urologe A 2007; 46 : 1485-99.
Kragelj B. Increased late urinary toxicity with whole pelvic radiotherapy after prostatectomy. Radiol Oncol 2009; 43 : 88-96.
Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Abdullah RSAR. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43 : 180-6.
Naji M, Hodolic
1. Crawford ED, Abrahamsson PA . PSA-based screening for prostatecancer: how does it compare with other cancer screening tests? Eur Urol 54: 262-273, 2008 .
2. Heinlein CA, Chang C . Androgen receptor in prostatecancer. Endocr Rev 25: 276-308, 2004.
3. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostatecancer. Prostate 28: 251-265, 1996.
4. Velcheti V, Karnik S, Bardot SF, Prakash O . Pathogenesis